BioSpace News Archive

BioForest

Why Amazon Could be More Interested in Medical Devices Than Drugs

Amazon, as most everyone knows, has its fingers in a lot of pies.

October 30, 2017

·

3 min read

·

Mark Terry

Policy

Insys Sales Execs Allegedly Made a Rap Video of Themselves Dancing With Their Deadly Fentanyl Spray

Insys continues to receive an optics beating in the wake of the charges against company founder John Kapoor and multiple executives surrounding illegal sales practices of its cancer pain drug.

October 30, 2017

·

3 min read

·

Alex Keown

Drug Development

Daiichi Sankyo’s Tumor Drug Meets Primary Endpoint in Late-Stage Study

Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint.

October 30, 2017

·

2 min read

·

Mark Terry

FDA

Allergan Receives Approval for Ozurdex (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)

Ozurdex is the first approved intravitreal injection for RVO in China.

October 30, 2017

·

7 min read

Business

Myomo to Report Third Quarter 2017 Results on November 6, 2017

The Company will host a conference call on Monday, November 6, 2017 at 4:30 p.m. EDT featuring remarks by Paul R. Gudonis, Chairman and Chief Executive Officer, and Ralph Goldwasser, Chief Financial Officer.

October 30, 2017

·

3 min read

Drug Development

SetPoint Medical Presents Early Data Showing Bioelectronic Medicine Accelerates Remyelination in Animal Model of Multiple Sclerosis

These results show promise for a possible bioelectronic treatment for MS and lay the groundwork for further studies by SetPoint.

October 30, 2017

·

3 min read

Deals

Hildred Capital Partners to Invest in Crown Laboratories

Hildred Capital Partners announced that Hildred has entered into an agreement under which it will assume a major stake in Crown Laboratories.

October 30, 2017

·

5 min read

Lone Star Bio

Neos Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from PDL BioPharma

NEOS Therapeutics today announced that its Board of Directors has unanimously rejected the October 26 unsolicited proposal from PDL BioPharma to acquire all of the outstanding shares of Neos for $10.25 per share in cash.

October 30, 2017

·

5 min read

Therapix Biosciences Initiates Non-clinical Studies for its Antibacterial Program in Collaboration With the Weizmann Institute of Science and Tel Aviv Sourasky Medical Center

Therapix has initiated non-clinical studies to evaluate the efficacy of its proprietary compound THX-150, a pharma composition of dronabinol in collaboration with the Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center.

October 30, 2017

·

7 min read

Business

Antares Vision North America and Xyntek Renew Strategic Partnership for U.S. Sales of Serialization Aggregation Solutions

Antares Vision has renewed its strategic partnership with Xyntek which means that Xyntek will continue to sell and service solutions in the Antares Track System platform throughout the U.S.

October 30, 2017

·

3 min read